Pol F. Boudes

CIK: 0001454771

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PLX

Protalix BioTherapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

PLX
Protalix BioTherapeutics, Inc.
Sep 3, 2026
Award(A)
Stock Options (Right to Buy)
Direct
17K shares-
PLX
Protalix BioTherapeutics, Inc.
Sep 3, 2026
Award(A)
Restricted Stock Units
Direct
8.5K shares-
PLX
Protalix BioTherapeutics, Inc.
Sep 3, 2025
Award(A)
Indirect
7.5K shares-

		Type	Shares	Price		Ownership
Sep 3, 2026	PLX Protalix BioTherapeutics, Inc.	Award(A) Stock Options (Right to Buy)	17,000	-	-	Direct
Sep 3, 2026	PLX Protalix BioTherapeutics, Inc.	Award(A) Restricted Stock Units	8,500	-	-	Direct
Sep 3, 2025	PLX Protalix BioTherapeutics, Inc.	Award(A)	7,500	-	-	Indirect

1-3 of 3 transactions

About Boudes Pol F

Boudes Pol F (SEC CIK 0001454771) files insider reports with the SEC as Director of Protalix BioTherapeutics, Inc. (PLX).

Signal8 holds 2 ownership filings by Boudes Pol F, all Form 4s, filed between Sep 4, 2025 and Sep 4, 2026. Those filings report 3 transactions, from Sep 3, 2025 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Boudes Pol F's filings is in CARMIEL.

Recent filings by Boudes Pol F

Sep 3, 2026: Grants or awards of PLX derivative securities (2 lines, Form 4, code A).
Sep 3, 2025: Grant or award of PLX shares (Form 4, code A).

Other insiders filing for Protalix BioTherapeutics, Inc. (PLX)

Schwartz Aharon, Director
Naos Yaron, Sr. VP & COO
Melincoff Gwen A, Director
Elze Christian, Director
Bar-Shalev Amos, Director
Bashan Dror, PRESIDENT AND CEO

How to read Form 4 transaction codes